Payment overview · 2025
General Payments
$33.39
2 reported records · 2 companies
Healthcare provider profile · identity verified
Amanda Hercules Smith, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BETHEL PARK, PA · NPI 1669787727
Verified facts
What the public records show
CMS Open Payments records show Amanda Hercules Smith, MD received $33.39 in general payments during 2025 across 2 reported records.
PFIZER INC. accounted for 50.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.97 | 50.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.42 | 49.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $33.39 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 110 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
110 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 726 | 240 |
| Levothyroxine Sodium | Levothyroxine Sodium | 382 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 355 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 325 | 96 |
| Lisinopril | Lisinopril | 275 | 91 |
| Metformin Hcl | Metformin Hcl | 179 | 57 |
| Gabapentin | Gabapentin | 161 | 39 |
| Losartan Potassium | Losartan Potassium | 161 | 53 |
| Simvastatin | Simvastatin | 146 | 51 |
| Sertraline Hcl | Sertraline Hcl | 130 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 32 |
| Eliquis | Apixaban | 110 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 33 |
| Alprazolam | Alprazolam | 102 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 31 |
| Furosemide | Furosemide | 93 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 26 |
| Omeprazole | Omeprazole | 80 | 28 |
| Carvedilol | Carvedilol | 78 | 25 |
| Famotidine | Famotidine | 78 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 25 |
| Potassium Chloride | Potassium Chloride | 76 | 30 |
| Warfarin Sodium | Warfarin Sodium | 76 | 14 |
| Trazodone Hcl | Trazodone Hcl | 70 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 22 |
| Tramadol Hcl | Tramadol Hcl | 68 | 22 |
| Alendronate Sodium | Alendronate Sodium | 65 | 26 |
| Atenolol | Atenolol | 65 | 21 |
| Jardiance | Empagliflozin | 62 | 18 |
| Allopurinol | Allopurinol | 61 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 19 |
| Montelukast Sodium | Montelukast Sodium | 54 | 21 |
| Ezetimibe | Ezetimibe | 50 | 17 |
| Synthroid | Levothyroxine Sodium | 50 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 18 |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | 12 |
| Clonazepam | Clonazepam | 39 | 11 |
| Spironolactone | Spironolactone | 37 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 12 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Valsartan | Valsartan | 36 | 11 |
| Farxiga | Dapagliflozin Propanediol | 34 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 12 |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Prednisone | Prednisone | 32 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 18 |
| Januvia | Sitagliptin Phosphate | 31 | 11 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Repaglinide | Repaglinide | 29 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $33.39 · 2 records | PFIZER INC. | ELIQUIS, NURTEC ODT, Ozempic | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error